Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis

Jean Kim 1,*, Kyle Miyazaki 1, Parthav Shah 1, Landon Kozai 1 and Jakrin Kewcharoen 2

1 Department of Internal Medicine, University of Hawaii, Honolulu, HI 96813, USA; kylesmiy@hawaii.edu (K.M.); parthavs@hawaii.edu (P.S.); lkozai@hawaii.edu (L.K.)
2 Division of Cardiovascular Medicine, Loma Linda University Health, Loma Linda, CA 92354, USA; jakrinkewcharoen@gmail.com
* Correspondence: jeankim@hawaii.edu

Abstract: Since the onset of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, various potential targeted therapies for SARS-CoV-2 infection have been proposed. The protective effects of mineralocorticoid receptor antagonists (MRA) against tissue fibrosis, pulmonary and systemic vasoconstriction, and inflammation have been implicated in potentially attenuating the severity of SARS-CoV-2 infection by inhibiting the deleterious effects of aldosterone. Furthermore, spironolactone, a type of MRA, has been suggested to have a beneficial effect on SARS-CoV-2 outcomes through its dual action as an MRA and antiandrogen, resulting in reduced transmembrane protease receptor serine type 2 (TMPRSS2)-related viral entry to host cells. In this study, we sought to investigate the association between MRA antagonist therapy and mortality in SARS-CoV-2 patients via systematic review and meta-analysis. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE and EMBASE databases were searched for studies that reported the incidence of mortality in patients on MRA with SARS-CoV-2 infection. Pooled odds ratio (OR) and 95% confidence interval (CI) of the outcome were obtained using the random-effects model. Five studies with a total of 1,388,178 subjects (80,903 subjects receiving MRA therapy) met the inclusion criteria. We included studies with all types of MRA therapy including spironolactone and canrenone and found no association between MRA therapy and mortality in SARS-CoV-2 infection (OR = 0.387, 95% CI: 0.134–1.117, \( p = 0.079 \)).

Keywords: COVID-19; SARS-CoV-2; coronavirus; mineralocorticoid receptor antagonist; aldosterone antagonist; spironolactone; meta-analysis

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was declared a pandemic by the World Health Organization (WHO) in March 2020 and has created a global health crisis with recurrent surges [1–3]. More than 350 million SARS-CoV-2 infection cases have been reported worldwide with over 5 million related deaths from the multisystemic disease. The pathophysiology and targeted treatment modality for SARS-CoV-2 remain unclear, however, and studies are underway.

A mineralocorticoid receptor antagonist (MRA) is an important part of guideline-directed medical therapy in heart failure with reduced ejection fraction and also used in chronic hypertension, primary aldosteronism, and ascites from liver cirrhosis [4–6]. MRAs inhibit the activity of aldosterone, the final effector of the renin–angiotensin–aldosterone system (RAAS), by blocking aldosterone receptors and preventing their deleterious effects such as electrolyte imbalance, endothelial dysfunction, smooth muscle cell proliferation of the blood vessels, glomerular injury in the kidneys, and myocardial inflammation and fibrosis. Spironolactone is a type of MRA that also has antiandrogenic properties, and
studies have implicated its potential effect on decreasing the severity of SARS-CoV-2 infection. In this study, we aimed to investigate the effect of MRA use on mortality in patients with SARS-CoV-2 infection through systematic review and meta-analysis.

2. Materials and Methods

2.1. Search Strategy

Two investigators (J.K. and K.M.) independently conducted a systematic search for published studies indexed in the MEDLINE and EMBASE databases from inception to December 2021, utilizing a search strategy that included the terms “SARS-CoV-2”, “COVID”, “COVID-19”, “coronavirus”, “mineralocorticoid receptor antagonist”, and “aldosterone antagonist”. Patients with all disease statuses and methods of conditioning regimens were included. There was no restriction on the types of mineralocorticoid receptor antagonist used, patients’ ethnicity, gender, race, age, data sources, or study location. Review articles, case reports, commentaries, and letters were excluded. A manual search for additional pertinent studies using references from the retrieved articles was also performed.

2.2. Study Inclusion Criteria

The eligibility criteria for inclusion of studies are the following:

(1) Randomized controlled trials (RCTs), cohort studies (prospective or retrospective), case-control studies, and cross-sectional studies that reported the incidence of mortality in patients who were infected with SARS-CoV-2 who were on MRA compared to those who were not on MRA therapy;

(2) Odds ratio (OR), hazard ratio (HR), or risk ratio (RR), and its corresponding 95% confidence intervals and p-values or sufficient raw data for these calculations had to be provided.

2.3. Data Extraction

Two investigators (J.K. and K.M.) independently performed a systematic review of studies following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [7]. A standardized data collection was conducted by obtaining the following information from each study: title, name of authors, year of publication, country of origin, the number of participants in the MRA therapy group, and the control (no MRA) group who have SARS-CoV-2 infection. In addition, information about the type of MRA, patients’ mean age, gender, and comorbid conditions was collected. Any conflict on the data extraction was resolved by the investigators’ consensus following discussions.

2.4. Quality Assessment of the Included Studies

The Newcastle–Ottawa quality assessment scale (NOS), ranging from 0 to 9, was utilized to evaluate each study in the following domains: recruitment and selection of the participants, similarity and comparability between the groups, and ascertainment of the outcome of interest among cohort studies [8]. The Cochrane Collaboration tool for assessing risk of bias was used to assess the quality of randomized controlled trial by assigning a score (high, low, or unclear) to individual element from five domains (selection, performance, attrition, reporting, and other).

2.5. Statistical Analysis

Meta-analysis of the included studies was performed to determine the pooled effect size with a 95% confidence interval (CI). The outcome of interest was the incidence of mortality in the MRA therapy group versus the control (non-MRA) group with SARS-CoV-2 infection. The heterogeneity of effect size estimates across the studies was quantified using the Q-statistic and the corresponding p-value or equivalent using the Higgins I-squared (I2) statistic [9]. In our study, meta-analysis was performed using the random-effects model, and the main results were summarized in a forest plot. To test the robustness of the results, a sensitivity analysis was performed by conducting meta-analyses excluding one study at a
time [10]. All meta-analyses were performed using STATA 16 software (StataCorp LLC, College Station, TX, USA).

3. Results
3.1. Study Search Results

Figure 1 shows a PRISMA flow diagram that depicts the process of identification, screening, eligibility, and inclusion or exclusion of the studies. The initial search of the PubMed and EMBASE databases yielded 58 articles. After title and abstract review, a total of 19 duplicate studies were removed, followed by elimination of three studies that were irrelevant to our study and eight studies conducted in animals or cellular models. Subsequently, 28 studies underwent full article review. Of these articles, nine studies were excluded because they were not of the appropriate type or design of study for our analysis, and 14 studies were eliminated as they did not have the outcomes of interest. The final analysis included five unique studies with a total of 1,388,178 subjects.

![PRISMA Diagram](image)

Figure 1. A PRISMA diagram depicting the search methodology and selection process.

3.2. Description of the Included Studies and Quality Assessment

A total of five studies with 1,388,178 subjects (80,903 subjects received MRA therapy) were included in our meta-analysis (one single-blind randomized-controlled study, two cross-sectional studies, and two case-control studies) [11–15]. The main characteristics of the included studies are described in Table 1. The mean age of subjects of the included studies ranged between about 50 to 70 years old, and the male gender constituted about 50% to 80% of total subjects in the studies. Regarding the type of MRA therapy, two studies utilized spironolactone [12,13], one study used canrenone [14], and two studies did not
specify the type of MRA [11,15]. Four studies provided the raw data for the incidence of mortality in patients with SARS-CoV-2 infection who received MRA therapy and those who did not receive MRA therapy and calculations were manually performed to obtain the OR and its corresponding 95% CI. On the other hand, Vicenzi et al. directly provided the value of OR and its corresponding 95% CI [14]. The Newcastle–Ottawa Scale (NOS) of the five studies ranged from 6 to 9 with a mean score of 8, reflecting a high quality of these studies. For the RCT study included in the meta-analysis, the Cochrane Collaboration tool for assessing the risk of bias was used. This showed a low risk of bias in most categories, except for the lack of double-blinding in the study design.

### Table 1. Main characteristics of the included studies (n = 5).

| Author     | Country | Published Year | Study Type                  | MRA (n = 80,903) | No MRA (n = 1,307,275) | Mean Age (Years) | Male (%) | HTN (%) | DM (%) | HLD (%) | MRA Type    |
|------------|---------|----------------|-----------------------------|------------------|------------------------|-----------------|----------|---------|--------|----------|-------------|
| Abbasi     | U.S.    | 2021           | Randomized-controlled trial | 50               | 87                     | 57.0             | 54.0     | 31.4    | 27.7   | NR       | Spironolactone |
| Ersoy      | Turkey  | 2021           | Case control                | 30               | 30                     | 58.8             | 80.0     | NR      | NR     | NR       | Spironolactone |
| Kocayigit  | Turkey  | 2020           | Cross-sectional             | 5                | 161                    | 65.8             | 46.7     | 100     | 34.9   | 16.6     | NR          |
| Savarese   | Sweden  | 2020           | Cross-sectional             | 80,788           | 1,306,958              | 73.5             | 52.1     | 79.8    | 28.7   | NR       | NR          |
| Vicenzi    | Italy   | 2020           | Case-control                | 30               | 39                     | 61.0             | 72.0     | 45.0    | NR     | 20.0     | Canrenone   |

Abbreviations: MRA, mineralocorticoid receptor antagonist; HTN, hypertension; DM, diabetes; HLD, hyperlipidemia; NR, not reported.

### 3.3. Quantitative Meta-Analysis Results

We assessed the presence of heterogeneity among the studies in terms of the Q-statistic and the corresponding p-value [9]. In the present case of p < 0.05, heterogeneity among studies existed. We quantified the degree of heterogeneity by using the I² statistic which indicated a substantial heterogeneity among the studies (I² > 50%). We employed the random-effects model to analyze the pooled effect size given substantial heterogeneity [16]. The incidence of mortality in patients with SARS-CoV-2 infection who received MRA therapy was not significantly lower than that of the non-MRA group (OR = 0.387, 95% CI: 0.134–1.117, p = 0.079). The forest plot demonstrating the pooled OR comparing mortality in patients with SARS-CoV-2 infection who received MRA therapy and those who did not receive MRA is shown in Figure 2.

**Figure 2.** A forest plot showing the OR (odds ratio) for the association of MRA therapy and incidence of mortality in SARS-CoV-2 infection.
3.4. Publication Bias

We aimed to investigate potential publication bias via the funnel plot and Egger’s test [17]. However, as we only had five studies included in the analysis, this number was insufficient to reject the assumption of no funnel plot asymmetry; thus, we did not perform a funnel plot or Egger’s test [18,19].

3.5. Sensitivity Analysis

To examine the robustness of the pooled OR and 95% CI of our study, sensitivity analyses were undertaken by excluding one individual study at a time [10]. When the study by Savarese et al. was removed, the result was statistically significant. Otherwise, no significant changes were noted when excluding other studies.

4. Discussion

The present study is the first systematic review and meta-analysis that investigated the incidence of mortality in SARS-CoV-2 infection who received MRA therapy compared to those who did not receive MRA therapy. Our study included all types of MRA therapy, and the results underscored that MRA therapy does not provide mortality benefit in patients with SARS-CoV-2 infection.

SARS-CoV-2 necessitates transmembrane protease receptor serine type 2 (TMPRSS2) to bind to an angiotensin-converting enzyme 2 (ACE2) receptor via proteolytic processing of the viral spike protein and becomes internalized to the host cell [20,21]. ACE2 has been identified as a key receptor for SARS-CoV-1 and SARS-CoV-2 to enter host cells and is expressed in essential organs including the lungs, heart, brain, and the kidneys in humans [22–24]. ACE2 serves as a counterregulatory enzyme of the renin–angiotensin–aldosterone system (RAAS), a cascade of vasoactive peptides that regulates blood pressure and fluid balance in the body, and degrades angiotensin II, thereby inhibiting its adverse effects such as acute lung injury, myocardial remodeling, vasoconstriction, sodium retention, and fibrosis [25–28]. Upon endocytosis of the viral complex, surface ACE2 levels are downregulated, and can result in angiotensin II accumulation and local activation of RAAS.

The interaction between SARS-CoV-2 and ACE2 has been proposed as a possible factor affecting the viral infectivity. Concerns about RAAS inhibitors affecting ACE2 levels have been previously raised; however, data in humans are limited. Experimental animal models have shown mixed findings on the effects of ACE inhibitors and angiotensin-receptor blockers (ARBs) on ACE2 levels [29,30]. Currently, experts warn about potential adverse clinical outcomes from abrupt withdrawal of RAAS inhibitors, and it is recommended to continue RAAS inhibitors in patients who are otherwise stable and are at risk for or have SARS-CoV-2 infection [31,32]. Recombinant ACE2 has been suggested to possibly normalize angiotensin II levels, and clinical trials are underway to assess whether recombinant ACE2 may restore balance in the RAAS cascade and prevent organ injury in patients with SARS-CoV-2 infection.

Androgen activity has also been implicated in SARS-CoV-2 infectivity and disease severity. Increased levels of circulating androgens contribute to a higher expression of transmembrane proteins such as TMPRSS2 that facilitate viral binding and entry into human cells by modulating viral spike proteins [33,34]. Early reports corroborating these findings have indicated that male gender is an independent risk factor for severe SARS-CoV-2 infection and that children tend to have milder disease courses than adults [35–37]. Subsequent studies have also shown that men with androgenic alopecia or anabolic androgenic steroid use, as well as women with hyperandrogenic states such as polycystic ovary syndrome (PCOS), can increase the risk for SARS-CoV-2 infection [38–41].

Finally, the protective effects of MRAs against tissue fibrosis, inflammation, and vascular dysfunction have been implicated in potentially attenuating the severity of SARS-CoV-2 infection by inhibiting aldosterone [33,42,43]. Previous authors have hypothesized that spironolactone, a type of MRA, may have a beneficial effect on SARS-CoV-2 outcomes through its dual action as an MRA and antiandrogen, resulting in reduced TMPRSS2-
related viral entry [38,44,45]. In animal models, spironolactone was also associated with reduction in oxidative stress and lung injury and has been considered a possible therapy in the treatment of COVID-19-related pulmonary fibrosis [42,46,47]. Despite the promising effects of this widely used drug, the effect of spironolactone on morbidity and mortality in patients with COVID-19 remains unclear, as the results of recent studies have been variable [48,49].

In our meta-analysis, we have included studies with all types of MRA therapy including spironolactone and canrenone, and have found that there is no association between MRA therapy and mortality in SARS-CoV-2 infection (OR = 0.387, 95% CI: 0.134–1.117, \( p = 0.079 \)). Despite its known effect of decreasing sympathetic activity, inflammation, tissue fibrosis, and the potential action of hindering viral entry to host cells, MRA therapy did not translate into a significant decrease in mortality in patients with SARS-CoV-2 infection. Mortality was chosen as the outcome of our interest as this particular outcome was consistently reported across the studies. However, it remains to be seen whether MRA therapy has association with other outcomes such as oxygen saturation, need for intubation or vasopressors, duration of hospitalization, and levels of inflammatory markers. Prospective clinical trials are currently underway to further elucidate the relationship between MRA therapy and morbidity and mortality in SARS-CoV-2 infection.

There are several limitations in our study. First, only one RCT was included in the analysis, while other studies were case-control and cross-sectional studies, making our analysis subject to unmeasured confounding factors which are inherent to observational study designs. Moreover, the types of MRA were varied and sometimes not reported in the studies, and the doses of MRA therapy received by patients were not uniform. Recent studies suggest possible beneficial effects of RAAS inhibitors and non-insulin anti-hyperglycemic agents against SARS-CoV-2 infection, and concurrent use of other medications such as angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), dipeptidyl peptidase-4 inhibitors (DPP4i), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor (GLP1) agonists reported in several of the included studies may have confounded the results [50–54]. Subsequently, an elevated heterogeneity was noted in our analysis (I² = 71.2%, \( p = 0.008 \)), and the random-effects model was employed in our meta-analysis to account for this heterogeneity. It is also notable that, in our sensitivity analysis, the result of the analysis when the study by Savarese et al. was removed was statistically significant. Of note, the study by Savarese et al. involved a much larger number of subjects in a nationwide registry population, compared to that of other studies (Table 1). Ultimately, the sensitivity analysis suggests that the findings of our study may need to be interpreted with caution.

5. Conclusions

In conclusion, our meta-analysis does not establish a significant association between MRA therapy and mortality in patients infected with SARS-CoV-2. Based on the lack of definitive benefit of MRA use in SARS-CoV-2 infection, clinicians should be cautious in initiating MRA therapy in these patients. Larger-scale randomized controlled trials with extended follow-up periods are needed to further elucidate the relationship.

Author Contributions: J.K. (Jean Kim) conceived the study, searched the literature, assessed the quality of the studies, performed statistical analysis and data interpretation, and wrote the original draft. K.M. searched literature, assessed the quality of the studies, and revised the manuscript. P.S. and L.K. participated in drafting the discussion. J.K. (Jakrin Kewcharoen) performed statistical analysis and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
Data Availability Statement: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. McFee, D.R.B. COVID-19 medical management including World Health Organization (WHO) suggested management strategies. Dis. Dm. 2020, 66, 101068. [CrossRef]
2. Li, J.; Lai, S.; Gao, G.F.; Shi, W. The emergence, genomic diversity and global spread of SARS-CoV-2. Nature 2021, 600, 408–418. [CrossRef] [PubMed]
3. Sanders, J.M.; Monogue, M.L.; Jodlowski, T.Z.; Cutrell, J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020, 323, 1824–1836. [CrossRef] [PubMed]
4. Kolkhof, P.; Bärfacker, L. 30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 2017, 234, T125–T140. [CrossRef]
5. Rico-Mesa, J.S.; White, A.; Ahmadian-Tehrani, A.; Anderson, A.S. Mineralocorticoid Receptor Antagonists: A Comprehensive Review of Finerenone. Curr. Cardiol. Rep. 2020, 22, 140. [CrossRef] [PubMed]
6. Colussi, G.; Catena, C.; Sechi, L.A. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J. Hypertens. 2013, 31, 3–15. [CrossRef]
7. Moher, D. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann. Intern. Med. 2009, 151, 264. [CrossRef]
8. Lo, C.K.L.; Mertz, D.; Loeb, M. Newcastle-Ottawa Scale: Comparing reviewers’ to authors’ assessments. BMC Med. Res. Methodol. 2014, 14, 45. [CrossRef]
9. Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [CrossRef]
10. Patsopoulos, N.A.; Evangelou, E.; Ioannidis, J.P.A. Sensitivity of between-study heterogeneity in meta-analysis: Proposed metrics and empirical evaluation. Int. J. Epidemiol. 2008, 37, 1148–1157. [CrossRef]
11. Kocayigit, I.; Kocayigit, H.; Yaylaci, S.; Can, Y.; Erdem, A.F.; Karabay, O. Impact of antihypertensive agents on clinical course and in-hospital mortality: Analysis of 169 hypertensive patients hospitalized for COVID-19. Rev. Da Assoc. Med. Bras. 2020, 66 (Suppl. 2), 71–76. [CrossRef] [PubMed]
12. Abbasi, F.; Adatorwovor, R.; Davarpanah, M.A.; Mansoori, Y.; Hajiani, M.; Azodi, F.; Sefidbakht, S.; Davoudi, S.; Rezaei, F.; Mohammadmoradi, S.; et al. A Randomized Trial of Combination Therapy, Sitagliptin and Spironolactone, in Hospitalized Adult Patients with COVID-19. J. Endocr. Soc. 2022, 6, bvac017. [CrossRef] [PubMed]
13. Ersoy, A.; Güven, B.B.; Ertürk, T.; Yurtseven, F.; Karaman, Z.; Güner, T.; Kömpe, Ö. COVID19 ARDS olgularında spironolaktonun etkinliğinin değerlendirilmesi Assessment of The Efficacy of Spironolactone For COVID-19 ARDS Patients. Aydın. Sağlık Derg. 2015, 7, 191–209. [CrossRef]
14. Vicenzi, M.; Ruscica, M.; Iodice, S.; Rota, I.; Ratti, A.; Di Cosola, R.; Corsini, A.; Bollati, V.; Aliberti, S.; Blasi, F. The Efficacy of the Mineralocorticoid Receptor Antagonist Canrenone in COVID-19 Patients. J. Clin. Med. 2020, 9, 2943. [CrossRef]
15. Savarese, G.; Benson, L.; Sundström, J.; Lund, L.H. Association between renin–angiotensin–aldosterone system inhibitor use and COVID-19 hospitalization and death: A 1.4 million patient nationwide registry analysis. Eur. J. Heart Fail. 2020, 23, 476–485. [CrossRef]
16. Kim, J.; Nishimura, Y.; Kewcharoen, J.; Yess, J. Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis. J. Clin. Med. 2021, 10, 3731. [CrossRef]
17. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [CrossRef]
18. Debray, T.P.A.; Moons, K.G.M.; Riley, R.D. Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: A comparison of new and existing tests: Detecting small-study effects. Res. Synth. Methods 2017, 9, 41–50. [CrossRef]
19. Simmonds, M. Quantifying the risk of error when interpreting funnel plots. Syst. Rev. 2015, 4, 24. [CrossRef]
20. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280.e8. [CrossRef]
21. Haslbauer, J.D.; Stalder, A.; Zinner, C.; Bassetti, S.; Mertz, K.D.; Went, P.; Matter, M.; Tzankov, A. Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19. Pathobiology 2021, 1–12. [CrossRef] [PubMed]
22. Qu, L.; Chen, C.; Yin, T.; Fang, Q.; Hong, Z.; Zhou, R.; Tang, H.; Dong, H. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. Int. J. Mol. Sci. 2021, 22, 11483. [CrossRef] [PubMed]
23. Hu, Y.; Liu, L.; Lu, X. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19? Front. Endocrinol. 2021, 12, 725967. [CrossRef]
24. South, A.M.; Diz, D.J.; Chappell, M.C. COVID-19, ACE2, and the cardiovascular consequences. *Am. J. Physiol.-Heart C* **2020**, *318*, H1084–H1090. [CrossRef] [PubMed]

25. Chen, Z.-W.; Tsai, C.-H.; Pan, C.-T.; Chou, C.-H.; Liao, S.-C.; Hung, C.-S.; Wu, V.-C.; Lin, Y.-H.; TAIPAI Study Group. Endothelial Dysfunction in Primary Aldosteronism. *Int. J. Mol. Sci.* **2019**, *20*, 5214. [CrossRef] [PubMed]

26. Patel, S.; Rauf, A.; Khan, H.; Abu-Izneid, T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. *Biomed. Pharmacother.* **2017**, *94*, 317–325. [CrossRef] [PubMed]

27. Mascolo, A.; Scavone, C.; Rafaniello, C.; De Angelis, A.; UrbaneK, K.; di Mauro, G.; Cappetta, D.; Berrino, L.; Rossi, F.; Capuano, A. The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19. *Front. Pharmacol.* **2021**, *12*, 667254. [CrossRef]

28. Ferrari, F.; Martinis, V.M.; Fuchs, F.D.; Stein, R. Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review. *Clin. Sao Paulo Braz.* **2021**, *76*, e2342. [CrossRef]

29. Kim, G.H.J.; Melgoza, A.; Jiang, F.; Guo, S. The effect of renin-angiotensin-aldosterone system inhibitors on organ-specific ace2 expression in zebrafish and its implications for COVID-19. *Sci. Rep.* **2021**, *11*, 23670. [CrossRef]

30. Vergara, A.; Jacobs-Cach, C.; Bosch, M.-M.-V.D.; Domínguez-Báez, P.; Benito, B.; García-Carro, C.; Serón, D.; Soler, M.J. Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model. *Mol. Cell. Endocrinol.* **2021**, *529*, 111263. [CrossRef]

31. Reynold's, H.R.; Adhikari, A.; Pulgarin, C.; Troxel, A.; Iturrate, E.; Johnson, S.; Hausvater, A.; Newman, J.; Berger, J.S.; Bangalore, S.; et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19. *N. Engl. J. Med.* **2020**, *382*, 2441–2448. [CrossRef] [PubMed]

32. Vaduganathan, M.; Vardeny, O.; Michel, T.; McMurray, J.J.V.; Pfeffer, M.A.; Solomon, S.D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19. *N. Engl. J. Med.* **2020**, *382*, 1653–1659. [CrossRef] [PubMed]

33. Kumar, N.; Zuo, Y.; Yalavarthi, S.; Hunker, K.L.; Kanthi, Y.; Obi, A.T.; Ganesh, S.K. SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. *Viruses* **2021**, *13*, 2209. [CrossRef]

34. Deng, Q.; Rasool, R.; Russell, R.M.; Natesan, R.; Asangani, I.A. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. *Science* **2021**, *365*, 102254. [CrossRef] [PubMed]

35. Gebhard, C.; Regitz-Zagrosek, V.; Neuhauser, H.K.; Morgan, R.; Klein, S.L. Impact of sex and gender on COVID-19 outcomes in Europe. *Biol. Sex. Differ.* **2020**, *11*, 29. [CrossRef]

36. Alkhouli, M.; Nanjundappa, A.; Annie, F.; Bates, M.C.; Bhatt, D.L. Sex Differences in Case Fatality Rate of COVID-19: Insights from a Multinational Registry. *Mayo Clin. Proc.* **2020**, *95*, 1613–1620. [CrossRef]

37. Mohamed, M.S.; Moulin, T.C.; Schiöth, H.B. Sex differences in COVID-19: The role of androgens in disease severity and progression. *Endocrine* **2021**, *71*, 3–8. [CrossRef]

38. McCoy, J.; Cadegiani, F.A.; Wambier, C.G.; Herrera, S.; Vaño-Galván, S.; Mesinkovska, N.A.; Ramos, P.M.; Shapiro, J.; Sinclair, R.; Tosti, A.; et al. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. *J. Eur. Acad. Dermatol. Venereol.* **2020**, *35*, e243–e246. [CrossRef]

39. Wambier, C.G.; Vaño-Galván, S.; McCoy, J.; Gomez-Zubiaur, A.; Herrera, S.; Hermosa-Gelbard, Á.; Moreno-Arrones, O.M.; Jiménez-Gómez, N.; Gonzalez-Cantero, A.; Fonda-Pascual, P.; et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”. *J. Am. Acad. Dermatol.* **2020**, *83*, 680–682. [CrossRef]

40. Goren, A.; Vaño-Galván, S.; Wambier, C.G.; McCoy, J.; Gomez-Zubiaur, A.; Moreno-Arrones, O.M.; Shapiro, J.; Sinclair, R.D.; Gold, M.H.; Kovacevic, M.; et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain—A potential clue to the role of androgens in COVID-19 severity. *J. Cosmet. Dermatol.* **2020**, *19*, 1545–1547. [CrossRef]

41. Schmidt, A.L.; Tucker, M.D.; Bakony, Z.; Labaki, C.; Hsu, C.-Y.; Shyr, Y.; Armstrong, A.J.; Beer, T.M.; Bijjula, R.R.; Bilen, M.A.; et al. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxalutamide for AndroCoV Trial. *Cureus* **2021**, *13*, e20691. [CrossRef] [PubMed]

42. Koftis, K.; Lechowicz, K.; Drozdzal, S.; Niedźwiedzka-Rystwej, P.; Wojdacz, T.; Grywalska, E.; Biernawska, J.; Wiśniewska, M.; Parczewski, M. COVID-19—the Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection. *Pharmaceuticals* **2021**, *14*, 71. [CrossRef] [PubMed]

43. Liaudet, L.; Szabo, C. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease. *Crit. Care Lond. Engl.* **2020**, *24*, 318. [CrossRef] [PubMed]

44. Cadegiani, F.A.; Zimmerman, R.A.; Fonseca, D.N.; Correia, M.N.; Muller, M.P.; Bet, D.L.; Slaviero, M.R.; Zardo, I.; Benites, P.R.; Barros, R.N.; et al. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxalutamide for AndroCoV Trial. *Cureus* **2021**, *13*, e20691. [CrossRef] [PubMed]

45. Zarehoseinzade, E.; Allami, A.; Ahmadi, M.; Bijani, B.; Mohammad, N. Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial. *Med. J. Islam. Repub. Iran* **2021**, *35*, 30. [CrossRef]

46. Wang, D.; Wilcoxon, C.S. Abstract MP30: Circulating SARS-CoV-2 Spike Protein 1 Causes Microvascular Oxidative Stress, Endothelial Dysfunction and Enhanced Thromboxane and Endothelin Contractility That Are Prevented by Spironolactone. Available online: https://www.ahajournals.org/doi/10.1161/hyp.78.suppl.1.MP30 (accessed on 27 August 2021).
47. Barut, F.; Ozacmak, V.H.; Turan, I.; Sayan-Ozacmak, H.; Aktunc, E. Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. *Clin. Investig. Med.* 2016, 39, 15–24. [CrossRef]
48. Wilcox, C.S.; Pitt, B. Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19? *J. Cardiovasc. Pharm.* 2020, 77, 323–331. [CrossRef]
49. Jeon, D.; Son, M.; Choi, J. Effect of Spironolactone on COVID-19 in Patients with Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea. *Front. Med.* 2021, 8, 629176. [CrossRef]
50. Moustafa, D.A.; Imran, Z.; Ismail, R.; Rayan, M.; Gadeau, A.-P.; Eidassouki, H.; Abdulrahman, N.; Mraiche, F. Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: Contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study. *Mol. Biol. Rep.* 2022, 49, 2321–2324. [CrossRef]
51. Li, X.-T.; Zhang, M.-W.; Zhang, Z.-Z.; Cao, Y.-D.; Liu, X.-Y.; Miao, R.; Xu, Y.; Song, X.-F.; Song, J.-W.; Liu, Y.; et al. Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19. *Int. J. Cardiol.* 2021, 336, 123–129. [CrossRef]
52. Li, X.-T.; Zhang, M.-W.; Zhang, Z.-Z.; Cao, Y.-D.; Liu, X.-Y.; Miao, R.; Xu, Y.; Song, X.-F.; Song, J.-W.; Liu, Y.; et al. Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19. *Int. J. Cardiol.* 2021, 336, 123–129. [CrossRef]
53. Sainsbury, C.; Wang, J.; Gokhale, K.; Acosta-Mena, D.; Dhalla, S.; Byrne, N.; Chandan, J.S.; Anand, A.; Cooper, J.; Okoth, K.; et al. Sodium-glucose-co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study. *Diabetes Obes. Metab.* 2020, 23, 14203. [CrossRef] [PubMed]
54. Sazgarnejad, S.; Yazdanpanah, N.; Rezaei, N. Anti-inflammatory effects of GLP-1 in patients with COVID-19. *Expert Rev. Anti-Infect.* 2021, 20, 373–381. [CrossRef] [PubMed]
55. Lee, J.H. Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension. *Med. Hypotheses* 2022, 158, 110739. [CrossRef] [PubMed]